Last reviewed · How we verify

Placebo Inhaltion Powder

GlaxoSmithKline · Phase 3 active Small molecule

Placebo Inhaltion Powder is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development.

A placebo inhalation powder that contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials.

At a glance

Generic namePlacebo Inhaltion Powder
SponsorGlaxoSmithKline
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Placebo formulations are inert substances designed to mimic the appearance, taste, and administration route of an active drug without providing any pharmacological effect. In this case, the placebo is formulated as an inhalation powder to match the delivery method of the investigational active drug being tested, allowing for blinded comparison in phase 3 clinical trials.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo Inhaltion Powder

What is Placebo Inhaltion Powder?

Placebo Inhaltion Powder is a Small molecule drug developed by GlaxoSmithKline.

How does Placebo Inhaltion Powder work?

A placebo inhalation powder that contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials.

Who makes Placebo Inhaltion Powder?

Placebo Inhaltion Powder is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is Placebo Inhaltion Powder in?

Placebo Inhaltion Powder is in Phase 3.

Related